PDCD1 and neoplasm: The improved systemic antitumor immunity and immune memory was further verified in spleens (Supplementary Fig. 44a–k) and tumor-draining lymph nodes (Supplementary Fig. 45a–l) of the R848@M2pep-MPsOVA and anti-PD-1 antibody-treated group.